Skip to main content
Journal cover image

A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury.

Publication ,  Journal Article
Lynch, JR; Wang, H; Mace, B; Leinenweber, S; Warner, DS; Bennett, ER; Vitek, MP; McKenna, S; Laskowitz, DT
Published in: Exp Neurol
March 2005

Although apolipoprotein E4 (APOE4) was initially identified as a susceptibility gene for the development of Alzheimer's disease, the presence of the APOE4 allele is also associated with poor outcome after acute brain injury. One mechanism by which apoE may influence neurological outcome is by downregulating the neuroinflammatory response. Because it does not readily cross the blood-brain barrier, the apoE holoprotein has limited therapeutic potential. We demonstrate that a single intravenous injection of a small peptide derived from the apoE receptor binding region crosses the blood-brain barrier and significantly improves histological and functional outcomes after traumatic brain injury (TBI). The development of an apoE-based intervention represents a novel therapeutic strategy in the management of acute brain injury.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Exp Neurol

DOI

ISSN

0014-4886

Publication Date

March 2005

Volume

192

Issue

1

Start / End Page

109 / 116

Location

United States

Related Subject Headings

  • Time Factors
  • Recovery of Function
  • Peptide Fragments
  • Neuroprotective Agents
  • Neurology & Neurosurgery
  • Movement Disorders
  • Mice, Inbred C57BL
  • Mice
  • Male
  • Low Density Lipoprotein Receptor-Related Protein-1
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lynch, J. R., Wang, H., Mace, B., Leinenweber, S., Warner, D. S., Bennett, E. R., … Laskowitz, D. T. (2005). A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol, 192(1), 109–116. https://doi.org/10.1016/j.expneurol.2004.11.014
Lynch, John R., Haichen Wang, Brian Mace, Stephen Leinenweber, David S. Warner, Ellen R. Bennett, Michael P. Vitek, Suzanne McKenna, and Daniel T. Laskowitz. “A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury.Exp Neurol 192, no. 1 (March 2005): 109–16. https://doi.org/10.1016/j.expneurol.2004.11.014.
Lynch JR, Wang H, Mace B, Leinenweber S, Warner DS, Bennett ER, et al. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol. 2005 Mar;192(1):109–16.
Lynch, John R., et al. “A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury.Exp Neurol, vol. 192, no. 1, Mar. 2005, pp. 109–16. Pubmed, doi:10.1016/j.expneurol.2004.11.014.
Lynch JR, Wang H, Mace B, Leinenweber S, Warner DS, Bennett ER, Vitek MP, McKenna S, Laskowitz DT. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol. 2005 Mar;192(1):109–116.
Journal cover image

Published In

Exp Neurol

DOI

ISSN

0014-4886

Publication Date

March 2005

Volume

192

Issue

1

Start / End Page

109 / 116

Location

United States

Related Subject Headings

  • Time Factors
  • Recovery of Function
  • Peptide Fragments
  • Neuroprotective Agents
  • Neurology & Neurosurgery
  • Movement Disorders
  • Mice, Inbred C57BL
  • Mice
  • Male
  • Low Density Lipoprotein Receptor-Related Protein-1